Cancer Research

Table of Contents

AACR American Association for Cancer Research

October 15, 2016 • Volume 76 • Number 20

BREAKING ADVANCES

CANCER RESEARCH 75TH ANNIVERSARY COMMENTARY

REVIEWS

PRIORITY REPORT

CLINICAL STUDIES

INTEGRATED SYSTEMS AND TECHNOLOGIES

Table of Contents

Table of Contents

Table of Contents

CORRECTIONS

AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

IL34 is expressed in primary lung adenocarcinoma tissues and correlates with poor prognosis in cancer patients. IL34, a cytokine that acts as a second ligand for CSF1R, was found to be induced and controlled by chronic activation of NF-κB in chemoresistant lung cancer cells. *In vitro* and *in vivo* experiments unveiled a dual role for IL34 in cancer chemoresistance. IL34 was found to enhance local immunosuppression by tumor-associated macrophages and also provides cancer cells with a critical survival signal to overcome chemotherapeutic conditions. For details, see article by Baghdadi and colleagues on page 6030.



AACR American Association for Cancer Research

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

76 (20)

Cancer Res 2016;76:5909-6133.